… are currently no therapies commercially available or in clinical development for the vision loss associated with … QR-110 for Leber’s congenital amaurosis 10 currently in clinical trials, and three additional pipeline programs, … 2018, and safety and efficacy results from the Phase 1/2 trial in Usher syndrome patients are expected in 2019. Usher …
… of 2016. “We continue to make great progress with our clinical development programs. Our first molecule, QR-010 for cystic fibrosis is in two active clinical trials and our second molecule, QR-110 for LCA10 is … The increase in expenses was primarily due to the clinicaltrial costs for QR-010 and clinic enabling studies for …
… today announced that the company will present pre-clinical data for QR-010 at the 39 th European Cystic … lead molecule, is currently being studied in two active clinical trials in patients with cystic fibrosis associated …
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today announced that Company management will pres